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ABSTRACT 
 
The objective of the project is to use aptamers, oligonucleotides designed to 
selectively bind target molecules, to develop a methodology for building an 
enzyme-linked aptasorbent assay (ELASA). This assay is designed to detect the 
presence of a target protein nucleolin that is overexpressed on the surface of 
cancer cells, and it would act as a novel diagnostic method for the disease. The 
success of our project would also confirm the feasibility of using an ELASA as a 
diagnostic tool to detect the presence of thrombospondin-1 (TSP-1), a protein 
known to experience glycosylation changes in human endometrioid ovarian 
cancer tissue. Our methodology will be based on that of existing ELASA 
“sandwich” type assays for analogous proteins, which incorporate the use of 
aptamers and antibodies. Aptamers offer inherent benefits over antibodies, which 
are the primary agents used in traditional enzyme-linked immunosorbent assays 
(ELISA), while demonstrating comparable sensitivity. Our developed ELASA has 
the potential to be an innovative diagnostic tool that can improve disease 
prognosis due to its high sensitivity and low limits of detection as an analytical 
method. 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
 
The objective of the project is to use aptamers, oligonucleotides designed to selectively bind 
target molecules, to develop an enzyme linked apta-sorbent assay (ELASA). This assay would 
act as an alternative to enzyme-linked immunosorbent assays (ELISA). The ELASA will detect 
the presence of a target protein that has been determined to be an early indicator of disease 
growth, and for that reason, it could be utilized as a novel diagnostic method for the disease. The 
success of our project would also confirm the feasibility of the use of an ELASA to detect the 
presence of thrombospondin-1 (TSP-1), a protein known to experience glycosylation changes in 
human endometrioid ovarian cancer tissue, and an ELASA could therefore act as a diagnostic 
tool for this deadly disease.1 Our method will be based on existing methodologies for ELASA 
“sandwich” type assays for analogous proteins, which incorporate the use of aptamers and 
antibodies. By using aptamers in the place of traditionally used antibodies as a diagnostic 
indicator of disease growth, this ELASA can become a useful alternative to more costly 
conventional diagnostic methods. 
1.2 Statement of Project Objectives 
 
We have three main objectives: 
1. To develop a methodology that will test serum samples for the presence of a target 
protein using a novel ELASA diagnostic system. 
2. Ensure that the ELASA system’s detection limits and sensitivity will be comparable to 
existing diagnostic techniques 
3. Confirm the resilience of the methodology in the testing of other protein targets such as 
TSP-1. 
1.3 Review of Field Literature 
 
Toh et al. discussed and promoted an emerging technique, ELASA, which is gaining popularity 
over ELISA, due to the inherent benefits of aptamers.2 Antibodies, which play key roles in an 
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ELISA as both the immobilized capture agent and the signaling agent, are expensive to 
manufacture, become unstable at room temperature, and are limited to only immunogenic target 
molecules. In comparison, aptamers are cheaper, more stable, and can specifically target an 
assortment of molecules while also being able to distinguish between minute differences in 
molecular structure. As a result, ELASAs can be more affordable, have longer shelf lives, and be 
utilized for a wider variety of applications.  
 
Toh et al. also explored various ELASA formats including the sandwich ELASA, which utilizes 
a capturing antibody or aptamer immobilized on a surface with a signaling aptamer that is 
modified for detection.2 The information provided in the paper will guide the design of our 
ELASA. An ELASA assay that completely replaces antibodies with aptamers would be ideal, but 
consequently the target molecule would need two different well-studied aptamers that bind 
selectively to two different regions. However, this is not the case for many target molecules, so a 
combination of antibodies and aptamers must be used. Our target molecule, nucleolin, only has 
one aptamer, AS1411, which was utilized by Guo et al., so we must also use an anti-nucleolin 
antibody for our sandwich assay.3 The associated antibody is commercially available, so it is 
obtain for research purposes. The article reviewed various ELASAs developed by other groups, 
and the materials and methods used in these studies will prove useful as we work to develop and 
optimize our own protocols. The sensitivity of these ELASAs were also provided, so they can act 
as a standard, to which we can compare our results, to see if our product can be competitive with 
existing ELASAs.  
 
In a study performed by Guo et al., nucleolin was used as a target molecule to direct drug 
delivery via PEG-PLGA nanoparticles to brain tumors.3 Nucleolin is a protein that is normally 
expressed in various parts of the cell. However, most notably, it is overexpressed on the surface 
of tumor cells, making it an effective biomarker for various types of cancer.4 In order to 
specifically target nucleolin, Guo et al. added an aptamer AS1411 to the surface of the 
nanoparticles.3 AS1411 is a well-studied aptamer sequence that has been isolated and identified 
for its specificity and selectivity for nucleolin. The 28 base-pair guanine-rich aptamer sequence 
is provided. This study initially sparked the idea to use nucleolin as our target molecule for our 
ELASA, as it is a highly researched molecule that is related to a popular disease-state. Although 
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we do not plan to utilize the AS1411 aptamer for drug delivery, it was useful to find a study that 
supports the efficacy of using this aptamer to target nucleolin.  
1.4 Existing Technologies  
 
Enzyme linked immunosorbent assays (ELISA) are one of the leading diagnostic techniques in 
clinical laboratories. It has been an industry mainstay due to the technique’s efficacy in 
determining the presence of a wide range of target molecules within any given sample, even at 
very low concentrations. These factors, in tandem with its compatibility with inexpensive 
detection instruments like spectrophotometers, have led to ELISA being the preeminent 
diagnostic technique in oncology and microbiology. 
 
ELISAs leverage the specific binding of antibodies to target antigens to indicate the presence of 
a certain target molecule. To produce a signal that can be in turn correlated to a specific target 
concentration via regression analysis, a secondary antibody coupled with a enzyme is then added 
to the solution. This antibody also binds to the target molecule and when the bound enzyme 
interacts with an added substrate, fluorescence is emitted and detected by a spectrophotometer. 
1.5 Project Significance  
 
Cancer continues to be one of the deadliest and most economically damaging diseases worldwide 
costing the cumulative world economy nearly $900 billion in 2008. In 2015, there were a total of 
8.2 million global deaths resulting from cancer with 65% of those deaths occurring in developing 
countries5. In developing nations, the high cost of health screenings and diagnostic tests can 
gravely affect the health of the community. The loss of the primary source of income for a family 
due to sickness on top of the cost for treatment can be a crippling prospect for families. To 
combat these staggering figures, early diagnosis of cancer, which can dramatically improve 
prognoses, must become a priority.  
 
The development of a successful methodology for an ELASA targeting nucleolin, would provide 
support for the use of ELASAs as a novel diagnostic method for numerous forms of cancer. Our 
methodology can then be applied to other target molecules that are relevant to various disease 
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states. One of these molecules, Thrombospondin-1 (TSP-1), is being studied by Dr. Steven 
Suljak at Santa Clara University’s Department of Chemistry and Biochemistry. TSP-1 undergoes 
specific glycosylation changes during early-stage endometrioid ovarian cancer, and it can 
therefore act as a biomarker for the disease. These specific yet minute changes in the structure of 
TSP-1 can be recognized by an aptamer, and when an adequate aptamer pool is selected for this 
glycosylation state of the protein, they can be utilized in an ELASA, which can serve as a novel 
diagnostic method for this disease. Currently, five-year survival rates are lower than 50%, but 
early-detection results in a 90% survival rate for patients who are diagnosed while the cancer is 
confined to the ovaries.1 Therefore, the development of a functional ELASA will support the 
efficacy of using aptamers in a diagnostic assay for various disease states, which can help 
improve survival rates.  
 
Additionally, ELASAs can be competitive alternatives to the traditional ELISA kits, which 
currently dominate the market. Aptamers can provide inherent benefits over antibodies, which 
will be explained in a later section, and because of this, an aptamer-based assay can be more 
rugged and more affordable. Currently, easy-to-use ELISA kits are available on the market for 
upwards of $700, and they must be refrigerated, making them incompatible with use in 
developing nations.6 As a result, an ELASA kit could become more accessible for developing 
nations that currently lack forms of diagnostic technologies due to insufficient funds and 
resources. In order to improve the quality of life for all and to continue the major growth of the 
emerging economies worldwide, it is essential that early diagnostic methods become more 
available.  
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CHAPTER 2: DETAILS OF KEY CONSTRAINTS 
2.1 Critique of Existing Technologies  
 
The enzyme linked immunosorbent assay, or ELISA, is among the most widely used diagnostic 
assay on the market. ELISAs work by combining the high affinities of antibodies to their target 
antigen in a controlled, wet lab environment. The antibody, which binds to the antigen found in a 
sample, can be conjugated, or linked, with an enzyme capable of releasing a colorimetric or 
fluorescent signal in the presence of substrate. B.K. van Weemen and A.H.W.M. Schuurs 
established this enzyme-based method as an alternative to radioactivity-based detections using 
the enzyme horseradish peroxidase (HRP) in 1971.7 In their initial findings the assay was able to 
detect the presence of a particular antigen with sensitivities of 80 ng/mL. Over 50 years later, 
ELISA assays are widely available and in use in clinical laboratories with sensitivities more than 
100-times smaller.  
 
Currently available ELISA assays vary in methodology and configuration at a molecular level. 
At a high level, there exists three main ELISA formats: indirect, blocking, and antigen capture. 
The indirect format uses an intermediate, non-enzyme-linked antibody to bind to a target 
molecule, or antigen, affixed to a solid surface. Then, a secondary enzyme-linked antibody, is 
introduced, which sandwiches the intermediate antibody and indicates the presence of the 
antigen in question. The blocking ELISA assay leverages the binding coefficients of two 
competing antibodies, one of which is enzyme-linked, with an antigen, to produce a colorimetric 
signal that is inversely proportional to the level of antigen present. 
 
Finally, an antigen capture, or “sandwich” ELISA, uses two pairs of antibodies, to capture an 
antigen in solution and signal its presence with an enzyme and its substrate. The capture antibody 
is either directly or indirectly immobilized onto a solid surface, and then binds to antigen in 
solution. Following a washing step, the enzyme-linked signal antibody is introduced, which 
binds to the antigen captured earlier. With the addition of the enzyme substrate, the level of 
antigen presence can be determined using absorbance or fluorescence spectrophotometry.  
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For the purposes of this project, the sandwich ELISA format and methodology will act as the 
general model. Sandwich ELISA formats are considered to be the most sensitive and robust on 
the market, and therefore are widely available for an array of antigens. Commercially available 
sandwich ELISA kits for the protein nucleolin, known to be over-expressed in cancerous tumor 
cells, tend to cost between $750 and $800 dollars and can reach a sensitivity under 0.057 ng/mL. 
Such ELISA kits are capable of testing tissue samples and other biological fluids for levels of 
nucleolin between 0.156 - 10 ng/mL.8  
 
Despite a low limit of detection, low sensitivity, and selectivity for a target protein, 
commercially available ELISA assays have several drawbacks. Firstly, costs for ELISA kits tend 
to be very high, mostly due to the antibodies included. Antibody development tends to be a 
lengthy, delicate, and resource intensive process, resulting in a high cost passed onto the 
consumer. Secondly, antibodies are heat and pH sensitive, leading to strict handling guidelines 
and short shelf lives. Antibodies, when properly handled may last for up to two years. However, 
ELISA kits containing enzyme conjugated or lyophilized antibodies tend to have shorter 
lifetimes. Thirdly, antibodies like IgG, a prolific immunoglobulin found in human plasma, are 
large molecules weighing around 150 kDa. Their large sizes can lead to less specific and 
selective binding characteristics than smaller molecules capable of binding at higher resolutions.  
2.2 Analysis of Key Constraints  
 
In designing an oligonucleotide alternative to the traditional ELISA sandwich assay, it is 
important to be aware of key parameters that will dictate its commercial success and laboratory 
efficacy. The key metrics in the design of an alternative assay are its sensitivity, limit of 
detection, and specificity for the target molecule. As mentioned earlier, nucleolin ELISA assays 
are capable of reaching a limit of detection of 0.156 ng/mL. Equally important in assay 
development is quantifying low levels of analyte in a sample. Nucleolin ELISA kits offer a 
sensitivity of 0.057 ng/mL. Finally, it is imperative that non-specific binding be minimized in 
order to avoid false positive readings for the target molecule. Non-specific binding occurs when 
a secondary antibody binds to a molecule, which is not the analyte, leading to higher than 
expected signal for a given amount of target molecule. ELISA kits prevent this by blocking the 
well plate before shipment, and including washing steps in the protocol. Similarly, this 
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phenomenon can be reduced in an alternative assay with careful blocking and washing steps 
written into the assay protocol. 
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CHAPTER 3: DESIGN DESCRIPTION 
3.1 Attributes of Oligonucleotides 
 
Aptamers are oligonucleotides, such as single-stranded DNA and RNA molecules, that are 
designed to target specific molecules. These molecules take on a unique 3-dimensional 
conformation to tightly bind to its target molecule and discern between minute structural motifs. 
Because of their specificity and selectivity in binding, aptamers are commonly used in 
applications where antibodies have traditionally been used.2 However, aptamers can bind to a 
wider range of molecules and because they are not immunologically active like antibodies they 
can be used within the body with less risk of adverse effects. Therefore, aptamers can be used in 
directed drug treatments in vivo.3  
 
The enhanced stability of aptamers allows them to be economical and efficient. Antibodies must 
remain refrigerated and will permanently denature if left out in temperatures near room 
temperature or higher. While aptamers should also be stored at cooler temperatures, aptamers 
can denature in suboptimal conditions, but they can return to their functional conformation and 
continue to bind to target molecules. This allows products containing aptamers to have a longer 
shelf life and be compatible in a wider range of environments.  
 
Additionally, the production of aptamers is simpler and cheaper than that of antibodies. Once a 
specific aptamer sequence is identified, they can easily be ordered from companies such as IDT 
and Thermo Fisher, who synthesize the desired sequences. Contrastingly, antibodies must be 
produced in batches through an arduous process that includes animal testing. This is not only 
more expensive and inefficient, but also this can result in batch-to-batch variabilities in 
antibodies, affecting the consistency of products.  
 
The unique attributes that aptamers offer have allowed them to be used in a variety of 
applications. They are gaining in popularity in the diagnostic field for their abilities to 
specifically and selectively bind to molecules. While antibodies have been a central component 
in traditional diagnostic assays, aptamers are an advantageous alternative. 
9  
3.2 Assay Overview 
 
Our hybrid assay utilizes a sandwich format depicted in Figure 1. In this type of assay, a 
capturing agent it immobilized onto a solid surface, such as a well-plate or chip. Here we utilize 
our antibody as the capturing agent. The target protein is then added, which binds to the 
immobilized capturing agent. A signaling agent is then introduced to bind to a separate region on 
the target, sandwiching the target protein between the capture and signaling agents. The 
signaling agent, in this case an aptamer, is conjugated with a signaling molecule, which allows 
detection via absorbance, fluorescence, or chemiluminescence. The observance of a signal would 
signify the presence of the target molecule, and without the target, no signal would occur.  
 
Figure 1. Pictorial depiction of a sandwich assay 
3.3 Antibody Immobilization 
 
The first step to building our hybrid assay requires us to immobilize our capture antibody onto 
the solid surface of the well-plate. We decided to look at two different methodologies for the 
immobilization. The simplest method is to use passive adsorption, in which the antibody binds to 
the plastic surface of the well-plate via hydrophobic interactions. In this method, the surface does 
not have to be pre-treated and the antibody is simply incubated at 37°C for several hours to allow 
for proper binding. However, this method results in the random orientation of antibodies. Figure 
2 shows the variability in orientation that can result from passive adsorption.  
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Figure 2. The random orientation that occurs during passive adsorption of antibodies onto a solid surface 
 
Antibodies are asymmetrical molecules, where the Fab region depicted in Figure 3 is unique to 
each type of antibody and is the site of antigen-binding.5 Contrastingly, the Fc region is common 
among all antibodies of a certain species and is not involved in the binding of the antigen. 
Therefore, if the Fab region is immobilized onto the plate, it is not available for antigen binding, 
which limits the assay’s ability to capture the target molecule. This results in a lower effective 
concentration, or the concentration of functional antibodies immobilized onto the surface.  
 
 
Figure 3. The labeled regions of an antibody 
 
In order to address the drawbacks of passive adsorption, we also wished to explore the use of 
Protein A to control the orientation of our antibody. Protein A is a surface protein normally 
expressed in the cell wall of the Staphylococcus aureus bacterium, and has the unique ability to 
bind to the Fc region of most antibodies.6 Because of this, Protein A can be coated onto a solid 
surface to immobilize the antibodies onto the surface in such a way that the Fab region is open to 
the environment for antigen binding (Figure 4). This results in an increased effective 
concentration and greater consistency. Analogous proteins such as Protein G and Protein A/G 
can also be used, but each have their strengths and weaknesses depending on the species from 
which the antibody was derived. Our anti-nucleolin antibody was rabbit-derived, so Protein A 
was the most appropriate for our assay. While Protein A offers a more effective immobilization 
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method, it is a more intensive process, as the surfaces need to be properly treated with Protein A. 
Luckily, this method has become popular in diagnostic assays and purification methods, so 
Protein A-coated surfaces are commercially available.  
 
Figure 4. Protein A-coated surface for oriented antibody immobilization 
 
We wished to build our assay using these different immobilization methods to observe any 
differences in results. While each method has benefits and drawbacks, in order to build the most 
effective hybrid assay, we wished to test both of these methods to see their effects on our overall 
product. 
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CHAPTER 4: EXPECTED RESULTS 
4.1 Detection Limits 
 
Detection limits of nucleolin ELISA assays range from 0.156 - 10 ng/mL. To compete and be 
efficacious, an ELASA assay must be able to detect analyte in a similar range. The development 
of our ELASA assay would be proven effective in terms of detection limits if able to produce a 
standard curve for nucleolin that lies within this range.  
4.2 Sensitivity  
 
We aim to compete with industry standard ELISA assays for nucleolin in terms of sensitivity. 
Therefore, to be successful on the market our ELASA assay must have sensitivities of 0.057 
ng/mL or better. Given the attributes of oligonucleotides compared with antibodies, it is 
plausible that our assay could improve upon the sensitivities seen advertised in commercially 
available ELISA kits for nucleolin. 
4.3 Efficacy as a Nucleolin Detector  
 
On top of achieving similar sensitivities and detection limits to commercially available ELISA 
kits, our aptamer-based must accurately detect heightened levels of nucleolin and show no signal 
for negative controls. For this reason, we will rigorously test the assay with and without crucial 
components present, and check for any non-specific binding that might lead to a false positive in 
a clinical setting. The presence of nucleolin, capture antibody, and aptamer can be removed to 
test the characteristics of the assay. Whenever each component of the ELASA assay is negatively 
controlled, we would expect no significant signal to appear. 
 
 
 
 
 
 
 
13  
CHAPTER 5: MATERIALS AND METHODS 
5.1 Materials 
 
We utilized two different well plates as the solid surface for our assay. One was an untreated 96-
well polystyrene plate, and the other was a Protein A-coated well plate from Thermo Fisher 
Scientific, Inc. in Waltham, MA. Buffers included a washing buffer of 0.1% TWEEN in 
phosphate buffered saline (PBS) and a blocking solution of 2% bovine serum albumin (BSA) in 
PBS. We obtained the anti-nucleolin antibody, AS22758, from Origene, Inc. of Rockville, MD. 
Recombinant human nucleolin protein was also purchased from Origene, Inc. The anti-nucleolin 
aptamer, AS1411, conjugated with Cy5 was produced by Integrated DNA Technologies (IDT) of 
Coralville, IA. All reagents are diluted to the desired concentrations in PBS. Finally, we utilized 
a 37°C incubator and a well-plate reader with fluorescence and absorbance capabilities during 
our testing. 
5.2 Hybrid Assay Methodology 
 
We begin our assay protocol by incubating 200 µL of the anti-nucleolin antibody in the well 
plate at 37°C for several hours. After the incubation is complete, each well is washed three times 
using 300 µL of washing buffer for each wash. This is followed by the addition of 200 µL of 
blocking buffer in each well and a 30 minute incubation at 37°C. When using the Protein-A 
coated well plates, this washing step is skipped because the plates are already pre-blocked. The 
wells are washed and then 200 µL of nucleolin is added to each well. After a one hour incubation 
at 37°C, the wells are washed and 200 µL of the aptamer is added to each well. A final washing 
step is conducted, and fluorescence readings are taken using an emission wavelength of 635 nm 
and an excitation wavelength of 665 nm, which were determined via a fluorescence wavelength 
scan performed on 10 µg/mL of aptamer. 
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CHAPTER 6: RESULTS 
6.1 Full Assay Results 
 
We ran our full assay methodology using both immobilization methods. In the passive adsorption 
assay, we ran n=4 of each assay condition, which included a full assay, partial assays containing 
only one or two assay components, and a blank. We also filled a well with 1 µg/mL of the 
signaling aptamer, which we used as a reference well. The signal we observed in this well would 
give us an idea of what signal would look like if we achieved it. 
 
Figure 5 shows the fluorescence readings of this assay using the previously stated wavelengths. 
No apparent signal was observed for the wells containing all of the assay components. 
Additionally, no signal was observed in the partial and blank assay conditions.  
 
 
 
Figure 5. Fluorescence readings of various assay conditions using passive adsorption for antibody immobilization 
 
Figure 6 shows the same assay conditions, but here Protein A-mediated binding was used as the 
antibody immobilization method. Again no apparent fluorescence signal was observed for the 
full assay condition, as well as the partial and blank assay conditions.  
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Figure 6. Fluorescence readings of various assay conditions using Protein A for antibody immobilization 
 
6.2 Immobilization Confirmation 
 
Since we could not achieve a signal using our full assay, we decided to evaluate the success of 
each step involved in building the assay. We began by evaluating the effectiveness of our 
immobilization methods. In order to confirm antibody immobilization using passive adsorption, 
we utilized a secondary antibody conjugated with horseradish peroxidase (HRP). First, we 
incubate our capture antibody in the well-plate to allow passive adsorption, and following a 
washing step the plate is blocked. Then, the plate is washed again and the secondary antibody is 
incubated at 37°C. During this process, the secondary antibody binds to the Fc region of the 
capture antibody that has successfully been immobilized onto the well plate surface (Figure 7). 
After the plate is washed, HRP substrate is added to the wells. When HRP is introduced to its 
substrate, a color change in the solution occurs causing the clear, colorless solution to turn blue. 
This color change is visible by the naked eye. Concentrated sulfuric acid is added to control the 
reaction and cause the color to change from blue to yellow. This yellow color can be detected 
and quantified via absorbance with greater sensitivity than the previous blue color, and it keeps 
the reaction from progressing too long.  
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Figure 7. The binding of HRP to the capture antibody for immobilization verification 
 
Figure 8 shows the absorbance readings obtained from this experiment with various 
concentrations of the capture antibody. While keeping the secondary antibody concentration 
constant, an increase in capture antibody concentration resulted in an increase in absorbance. 
These results confirm the immobilization of our antibody onto the surface of the well plate.  
 
 
Figure 8. Absorbance readings taken at 450 nm for various concentrations of antibody immobilized via passive 
adsorption 
 
6.3 Varied Protein Concentration Results 
 
Since we did not achieve the expected signal in the full assay condition, we performed the assay 
protocols again, but we used increased and varied nucleolin concentrations. By varying the 
concentration, we could see which concentrations of nucleolin could achieve sufficient binding 
to both the antibody and aptamer to produce a signal. We also added an excess of aptamer to 
ensure that this component would not limit the success of our assay. In Figure 9, no signal was 
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recorded for any of the protein concentrations. Again, a well containing the fluorescently labeled 
aptamer was used as a reference.  
 
Figure 9. Fluorescence readings for passive adsorption assays carried out with various protein concentrations 
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CHAPTER 7: DISCUSSION 
7.1 Lack of Signal 
 
Although we expected a positive correlation between nucleolin concentration and fluorescence, 
this was not realized in our experimental results. Signal remained low for wells containing 
nucleolin, and mirrored the results seen in the “blank” or negative control well. For this reason, 
we hypothesize that there is a lack of expected binding behaviors between either the capture 
antibody and nucleolin, aptamer and nucleolin, or both. If either pair failed to bind with a low 
disassociation constant, this would negatively impact the end results of the assay. As the 
sandwich conformation of the assay is constructed, it is imperative that each addition component 
binds selectively with the target protein. 
 
It is also possible that the lack of signal in our assay is due to flaws in our protocol that led to 
interference between the binding of aptamer and protein or protein and antibody. Between each 
incubation step, the well plate is washed thoroughly with a dilute surfactant to decrease the 
chance of non-specific binding. Although such washing steps are critical, it is possible that either 
the physical or chemical forces introduced lead to a disassociation between assay components, 
thus diminishing the overall signal detected.  
7.2 Non-specific Binding 
 
A positive takeaway from experimentation with our assay protocol is a lack of non-specific 
binding. Non-specific binding occurs when assay components, like antibody or aptamer, bind 
non-specifically and unexpectedly to other areas than their intended target. This increases the 
signal of the assay disproportionately to the level of protein in a sample. Therefore, in a 
commercial application, an assay with high non-specific binding would lead to a false positive 
reading, potentially leading to a misdiagnosed decision.  
 
In order to mitigate non-specific binding and false positives in our assay, the protocol was 
constructed with a blocking step. Addition of bovine serum albumin into the well plate covers 
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areas where non-specific binding might occur, ensuring that antibody and aptamer will bind only 
at discrete, expected sites upon the tested protein.  
 
With low levels of fluorescence seen in our blank wells, we were able to prove that such 
blocking steps were successful in preventing non-specific binding. The entire assay protocol was 
also tested with certain components, like antibody and aptamer, removed. Similarly, this returned 
a low level of fluorescence, suggesting that non-specific binding was not occurring at a 
significant level.  
7.3 Future Work  
 
Several auxiliary experiments can be run to further identify the possible sources of error within 
our assay protocol that are resulting in an unexpected lack of signal. In order to determine the 
level of binding occurring between aptamer and protein, and also antibody and protein, analysis 
of each pair can be completed with capillary electrophoresis and surface plasmon resonance. 
 
Capillary electrophoresis is a separation technique that can effectively discriminate between 
molecules and bound compounds with respect to charge and size. By incubating nucleolin in 
solution with antibody, and separately with aptamer, the level of binding can be determined 
using fluorometric detection. A tested material is drawn through a glass capillary, microns in 
diameter, with an applied potential. As the solution is pulled across a clear glass window, laser 
light is applied at a wavelength specific to the excitation wavelength of the signaling molecule in 
solution. Fluorescence readings then indicate when a molecule elutes from the capillary. This 
process can help to quantify the level of binding between an aptamer and its target, as heavier 
bound states will elute later than unbound free molecules.  
 
It should be noted that in the case of testing binding between antibody and protein, another 
secondary antibody, conjugated with a fluorescing molecule, must be used. Unlike in the case of 
the anti-nucleolin aptamer, the capture antibody lacks a conjugated signaling molecule. 
Therefore, in an analytical method that relies on fluorescence, like capillary electrophoresis, a 
conjugated secondary antibody, an auxiliary source of fluorescent signal, must be included in the 
incubation process between antibody and protein. 
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Another analytical method capable of determining levels of binding between each assay 
component is surface plasmon resonance (SPR). This technique relies on monitoring the angle of 
reflection of an incident light source that is affected by the binding of a target to a capture 
molecule. In the context of our assay design, the capture antibody or aptamer could be affixed to 
a solid state, often times gold plated surface, and be monitored for their respective binding to 
nucleolin. As more molecules bind to the target protein, the reflective angle changes, allowing 
for a precise calculation of the disassociation constant (Kd) between two species. 
 
Prior to exploring the binding between each assay component using more sophisticated 
technology, it might be worthwhile to determine levels of binding between the capture antibody 
and nucleolin with a more basic method. Using a signaling antibody, included in a commercially 
available ELISA kit, the binding of a protein to the immobilized capture antibody on the well 
plate surface can be determined. By following our protocol steps preceding the addition of 
aptamer to the well, and then adding a conjugated antibody instead, the source of error can be 
more reliably isolated before completing more robust testing.  
 
i  
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